For example, genomic biomarkers such as EGFR and BRCA1/2 mutations guide targeted therapies like EGFR inhibitors (erlotinib, gefitinib) for NSCLC and PARP inhibitors (olaparib, niraparib) for BRCA1/2‐mutated breast and ovarian cancers [14, 374]. The gene discussed is EGFR; the disease is ovarian carcinoma.